NCT06565026View on ClinicalTrials.gov

CS-206 in Patients With Sickle Cell Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Sickle Cell Disease
Interventions
GENETIC

CS-206

Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Guangxi Medical University, Nanning

Sponsors
All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

lead

CorrectSequence Therapeutics Co., Ltd

INDUSTRY